Choice of Oral Presentations

Prostate Cancer

Joaquin Mateo, Nuria Porta, Ursula Brigid McGovern, Tony Elliott, et al.

TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.


Conclusions: Olaparib has antitumor activity against heavily pre-treated mCRPC with DDR gene defects, with BRCA1/2 aberrant tumors being most sensitive but with confirmed responses in patients with other DDR alterations. Clinical trial information: NCT01682772


Kim N. Chi, Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, et al.

First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Conclusions: In the TITAN study in pts with mCSPC, including pts with high- and low-volume disease and prior docetaxel, addition of APA to ADT significantly improved rPFS and OS, and the safety profile was tolerable. These results support the addition of APA to ADT for tx of pts with mCSPC. Clinical trial information: NCT02489318


Michael J. Morris, Glenn Heller, Alan Haruo Bryce, Andrew J. Armstrong, et al.

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

Conclusions: Addition of abiraterone acetate to enzalutamide did not prolong survival in men with mCRPC. The combination resulted in more AEs than enzalutamide alone. Support: U10CA180821, U10CA180882, U24CA196171; Clinical trial information: NCT01949337

Metastatic Renal Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, Rustem Gafanov, et al.
Conclusions: Pembro + axi provides benefit in the combined population of pts with IMDC intermediate or poor risk and in pts whose tumors had sarcomatoid features. The observed benefits were consistent with those seen in the total population. Clinical trial information: NCT02853331
Jianjun Gao, Jose A. Karam, Nizar M.  et a.Tannir, Matthew T Campbelll.
Conclusions: IC therapy plus CS is safe and beneficial to patients with MRCC and therefore, warrants testing, along with a few correlative biomarkers, in a larger phase 3 trial. Clinical trial information: NCT 02210117.

Metastatic Urothelial Cancer

Jonathan E. Rosenberg, Karla V. Ballman, Susan Halabi, Colleen Watt, et al.
Conclusions: The addition of bevacizumab to GC chemotherapy did not result in improved OS (primary endpoint) in patients with mUC but there was a PFS improvement. The observed median OS of about 14 months is consistent with prior phase III trials of cisplatin-based chemotherapy. Support: U10CA180821, U10CA180882, U10CA180820, U10CA180853, U10CA180888, Genentech Clinical trial information: NCT00942331
Matt D. Galsky, Sumanta K. Pal, Amir Mortazavi, Matthew I. Milowsky, et al.

Conclusions: Switch maintenance pembro may “deepen” responses achieved with 1st-line chemotherapy. Switch maintenance pembro prolongs PFS in pts with mUC completing 1st-line platinum-based chemotherapy. Clinical trial information: NCT02500121

Baseline Characteristics.

  Placebo (N=52) Pembro (N=55)
Age, median (range) 65 (44-87) 68 (41-83)
Pre-chemo metastatic disease    
Visceral metastases 32 (62%) 39 (71%)
No visceral metastases 20 (38%) 16 (29%)
Median # cycles of 1st line chemo 6 5
Response to 1st line chemotherapy    
CR/PR 36 (69%) 40 (73%)
SD 16 (31%) 15 (27%)
1st line chemo    
Carboplatin-based 11 (21%) 16 (29%)
Cisplatin-based 41 (79%) 39 (71%)


Clinical Science Symposium

Toni K. Choueiri, Laurence Albiges, John B. A. G. Haanen, James M.G. Larkin, et al.

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). 

Conclusions: These findings define molecular features that differentiate therapy-specific outcomes in first-line aRCC and may inform personalized therapy strategies for pts with aRCC. Funding: Pfizer and Merck KGaA. Clinical trial information: NCT02684006